- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Oxford Immunotec Global is a diagnostics & research business based in the US. Oxford Immunotec Global shares (OXFD) are listed on the NASDAQ and all prices are listed in US Dollars. Oxford Immunotec Global employs 273 staff and has a trailing 12-month revenue of around $57.3 million.
|52-week range||$0.00 - $0.00|
|50-day moving average||$21.94|
|200-day moving average||$16.48|
|Wall St. target price||$22.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.18|
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Oxford Immunotec Global stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oxford Immunotec Global's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oxford Immunotec Global's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Oxford Immunotec Global shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$57.3 million|
|Gross profit TTM||$54.4 million|
|Return on assets TTM||-4.99%|
|Return on equity TTM||-8.19%|
|Market capitalisation||$562.5 million|
TTM: trailing 12 months
We're not expecting Oxford Immunotec Global to pay a dividend over the next 12 months.
Over the last 12 months, Oxford Immunotec Global's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oxford Immunotec Global's is 1.3781. This would suggest that Oxford Immunotec Global's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT. TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT. CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.